Thinly traded micro cap vTv Therapeutics (NASDAQ:
VTVT) jumps
67% premarket on robust volume on the heels of
positive results from Part 2 of a Phase 2 clinical trial,
Simplici-T1, evaluating TTP399 as oral adjunctive therapy to insulin in adults with type 1 diabetes (T1D).
Treatment with once-daily TTP399 resulted in
statistically significant improvements in HbA1C compared to placebo at
week 12 (p=0.03). Specifically, treated patients experience a 0.21%
reduction in HbA1C versus a 0.11% increase in the control group (from an
average baseline of 7.6%).
Also, the addition of TTP399 reduced total daily mealtime bolus insulin by 11% from baseline (p=0.02).
A registration trial is next up.
According to the company,
TTP399 activates
an enzyme called glucokinase (GK) which is a key regulator of glucose
levels, adding that it only activates GK in the liver thereby avoiding
disruption in the interaction between GK and glucokinase regulatory
protein which can lead to hypoglycemia, limited durability of response
and other side effects, problems that have dogged other GK activators.
